AVJ-514 Japan Trial

计划入组 30 人 · 首次发布于 2015 年 8 月 11 日

A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)

计划入组 25 人 · 首次发布于 2020 年 10 月 5 日

A Phase 1 Study to Evaluate the Safety and Tolerability of CBL-514 Injection on Convexity or Fullness of Abdominal Subcutaneous Fat in Healthy Volunteers

计划入组 40 人 · 首次发布于 2021 年 1 月 7 日

IMPT-514

CKD-510

CKD-512

CKD BIO CORPORATION

Italy

QED Therapeutics, Inc.

United States

Sunnybrook Research Institute

Canada

Chong Kun Dang Showcases Three Promising Drug Candidates at Major U.S. Medical Conferences

Caliway's CBL-514 Receives EMA Orphan Drug Designation for Dercum's Disease

Caliway's CBL-514 Receives EMA Orphan Drug Designation for Dercum's Disease